Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic)

Page 68 of 2018-19 Annual Report: [Section is General Shareholder Information].

The Company imports API/Intermediates/Key Starting Material (KSM)
which may be prone to commodity price risk. The Company does not
do any hedging except strategic procurement at times.

China is not mentioned specifically. I don’t know if the import trade data tracking through sites like Zauba still gives company wise details. Without customs data, it would be difficult to know.

2 Likes